ReviewCureus2021
A Review of Epidemiology and Cancer Biology of Malignant Melanoma.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review.International journal of clinical oncology · 2025Pooled it
- RSL24D1 links ribosome biogenesis to p53 activation in melanoma.Cancer gene therapy · 2026Article
- Presenilin-1 Affects Melanoma Cell Behavior in an Amyloid Precursor Protein-Rich, Alzheimer's Disease-like, Microenvironment.International journal of molecular sciences · 2026Article
- Prognostic Value of Neutrophil Percentage-Albumin Ratio in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2026Article
- Relationships Between the Microvascular Network and Mast Cell Density in Malignant Melanoma.Medicina (Kaunas, Lithuania) · 2026Article
- Pregnancy Associated Melanoma: Diagnostic and Therapeutic Challenges.Medicina (Kaunas, Lithuania) · 2026Review
- Article
- Review
- Cutaneous melanoma in Kazakhstan: epidemiological trends and economic burden on the healthcare system.Archives of public health = Archives belges de sante publique · 2026Article
- Unveiling the Advances in Protein Kinase: From Concept to Clinic.Current protein & peptide science · 2026Review
- Clinical and Histopathological Prognostic Factors for Disease-Free Survival in Early-Stage Acral and Non-Acral Cutaneous Melanoma: A Retrospective Asian Cohort Analysis.Cancer management and research · 2026Article
- Standardized Incidence Ratio of Melanoma by Industry Groups in Korea.Safety and health at work · 2025Article
- Global assessment of surface ultraviolet radiation and malignant skin melanoma incidence from 1990 to 2021.Scientific reports · 2025Article
- Potential Risk of Cutaneous Melanoma Attributable to Medication Use: A Mendelian Randomization Approach.Biomedicines · 2025Article
- The Role of ROS-Mediated Mitochondrial Dysfunction in the Development of Malignant Melanoma.Experimental dermatology · 2025Review
- Integrated spectroscopic and morphological analyses reveal cellular shifts in gene-silenced melanoma CSCs.Scientific reports · 2025Article
- A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- MIAT: A pivotal oncogenic long noncoding RNA tunning the hallmarks of solid malignancies.Translational oncology · 2025Article
- A Unique Signature for Cancer-Associated Fibroblasts in Melanoma Metastases.Pigment cell & melanoma research · 2025Article
- Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma is a neoplasm originating in the melanocytes in the skin. Although malignant melanoma is the third most common cutaneous cancer, it is recognized as the main cause of skin cancer-related mortality, and its incidence is rising. The natural history of malignant melanoma involves an inconsistent and insidious skin cancer with great metastatic potential. Increased ultra-violet (UV) skin exposure is undoubtedly the greatest risk factor for developing cutaneous melanoma; however, a plethora of risk factors are now recognized as causative. Moreover, modern oncology now considers melanoma proliferation a complex, multifactorial process with a combination of genetic, epigenetic, and environmental factors all known to be contributory to tumorgenesis. Herein, we wish to outline the epidemiological, molecular, and biological processes responsible for driving malignant melanoma proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.